RT Ethereum Foundation (@ethereumfndn)0/ Earlier this week, the EF finalized the terms of a 10,000 ETH sale at an average price of $2,572.37 via OTC.For this sale, our OTC counterparty was @SharpLinkGaming. ...

Just got off a call with my buddy who works at the biggest OTC desk in crypto and they literally are down to their last 17 BTC.Do with that what you will ...

🔥 TODAY: SharpLink Gaming just scooped up another 1,989 $ETH ($4.82M) via OTC. https://t.co/QiOZaBEuSP ...

公司2024率先启动学术营销模式转型，推进"潘医生工程"，虽然短期内面临转型压力， 但增强了核心产品的放量潜力。 公司深化精细化分层分线销售，根据产品特性和治疗领域差异划分销售线，对金振口服 液、杏贝止咳颗粒等品种实施专人专做；逐步强化OTC布局，提升终端覆盖率，实现多业 态并举，20 2 4年公司销售费用支出15.35亿元，同比下降20. 7%。 此外，公司研发管线价值得到体现， 2024年收购中新医药完善生物药领域的研发布局， 自身在中药、化学药和生物药领域也有多个品种陆续进入临床或者获批上市阶段。 主题一 梁 广 楷 预 计 20 2 5 - 2027 年 将 实 现 归 母 净 利 润 4.4/ 5.3/ 6.3 亿 元 ， 同 比 增 长 1 3 .0%20.2%/ 1 8 . 4%，对应PE为21/ 17/ 15倍。 医药板块经过4年调整，疫情受益高基数、医保局控费超预期、医疗反腐冲击等负面预期 逐步消化，机构相对低配。与此同时，中国医药产业经过持续创新转型，在全球市场的认 可度和影响力快速提升。 该公司是 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the pharmaceutical industry [8]. Core Insights - The overall retail sales of traditional Chinese medicine (TCM) in pharmacies showed a year-on-year decline in Q1 2025, indicating pressure on the market [3][19]. - The report highlights stable rankings among major products in various therapeutic areas despite the overall sales decline [18]. Summary by Sections Overall Situation - The retail sales of TCM in pharmacies increased from 143.9 billion yuan in 2017 to 168 billion yuan in 2024, with a compound annual growth rate (CAGR) of 2.23%. However, Q1 2025 sales were 41.2 billion yuan, down 7.67% year-on-year, attributed to regulatory pressures and consumer downgrade [3][19]. Therapeutic Areas - **Cold and Heat Relief**: Sales decreased by 6.90% year-on-year in Q1 2025, with sales reaching 7.3 billion yuan, influenced by lower respiratory disease cases compared to the previous year [4][22]. - **Nutritional and Health Supplements**: Sales slightly declined by 1.01% year-on-year in Q1 2025, totaling 5.8 billion yuan, impacted by consumer downgrade and high sales in the previous year [5][25]. - **Cardiovascular Health**: Sales showed a slight decline of 2.98% year-on-year in Q1 2025, with sales at 10.4 billion yuan, reflecting stable market demand [6][28]. - **Musculoskeletal Health**: Sales increased by 0.68% year-on-year in Q1 2025, reaching 3.7 billion yuan, indicating long-term growth potential due to aging demographics [14][31]. - **Gastrointestinal Health**: Sales grew by 7.13% year-on-year in Q1 2025, totaling 16 billion yuan, reflecting a recovery in demand [34]. - **Cough and Phlegm Relief**: Sales dropped significantly by 26.80% year-on-year in Q1 2025, amounting to 4.8 billion yuan, primarily due to a high base effect from the previous year [15][37].

Citigroup (C) 2025 Conference June 10, 2025 07:30 AM ET Speaker0 we can. All right. So thank you so much for joining us this morning. I have to read a disclosure For important disclosures, please see the Morgan Stanley Research disclosure website at morganstanley.com/researchdisclosures. Taking a photograph and the use of recording devices is also not allowed. This is meant to if you have any questions, please reach out to your Morgan Stanley sales representative. Okay. Thank you so much. With that out of t ...

Group 1 - The focus has shifted towards offshore drilling, supply industry, and shipping, including tankers, containers, and dry bulk [1] - The fuel cell industry is being monitored as it is still in its early stages of development [1] Group 2 - The individual has extensive experience in navigating significant market events such as the dotcom bubble, the aftermath of the World Trade Center attacks, and the subprime crisis [2] - The individual has a background in auditing with PricewaterhouseCoopers before transitioning to day trading [2]

Group 1 - The focus has shifted towards offshore drilling, supply industry, and shipping, including tankers, containers, and dry bulk [1] - The fuel cell industry is being monitored as it is still in its early stages of development [1] Group 2 - The individual has extensive experience in auditing with PricewaterhouseCoopers before transitioning to day trading nearly 20 years ago [2] - Successfully navigated significant market events such as the dotcom bubble, the aftermath of the World Trade Center attacks, and the subprime crisis [2]

Group 1 - The focus has shifted from primarily tech stocks to include offshore drilling, supply industry, and shipping sectors such as tankers, containers, and dry bulk [1] - There is an emerging interest in the fuel cell industry, which is still in its nascent stage [1] Group 2 - The individual has extensive experience in auditing with PricewaterhouseCoopers before transitioning to day trading nearly 20 years ago [2] - The individual successfully navigated significant market events including the dotcom bubble burst, the aftermath of the World Trade Center attacks, and the subprime crisis [2]

而在政策方面，国内政策环境变化也为板块修复提供关键支撑。2025年政府工作报告首次提出"健全药 品价格形成机制，制定创新药目录"，明确将未被医保覆盖的高价值创新药（如ADC、双抗）纳入丙类 目录试点，直接推动其商业化放量。同时，医保谈判规则趋于稳定，部分企业利润压力得到缓解。 与此前仿制药集采引发的行业震荡不同，本轮政策更注重创新导向。政策层面对"真创新"的倾斜，使得 具备持续研发能力的药企估值修复速度领先行业。葛兰在中欧医疗创新的一季报中明确表示，将继续在 创新药械及其产业链、OTC、消费医疗等领域进行重点配置。她看好创新药持续突破、消费医疗复苏与 产业链关键环节国产替代等方向。 无论是从市场面还是政策面来看，创新药及其相关产业链都将迎来更为有利的发展机遇。未来随着更多 创新药的成功问世和市场的不断拓展，我们有理由相信医药健康板块将会迎来更加美好的明天。 在经历了医药健康板块的起伏波动后，葛兰们迎来了又一重要时刻。近期，沉寂数年的医药健康板块迎 来显著反弹，Wind数据显示，截至4月末，Wind创新药指数年内累计涨幅超20%，港股创新药板块更以 近50%的涨幅领跑市场。4月22日，中证港股通医药卫生综合指数 ...